Please assess the completion status of the following clinical trial:

Trial Title: A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Subjects must be willing and able to give signed and dated written informed consent~* Patients with Type 2 diabetes mellitus (T2DM) with inadequate glycemic control~* Subjects should have been taking the same daily dose of metformin ≥ 1500 mg~* Fasting Plasma Glucose ≤ 270 mg/dL (≤15 mmol/L)~* Males and females, aged ≥18 years old at time of screening visit~* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test~* WOCBP and males must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug~Exclusion Criteria:~* Clinical diagnosis of type I diabetes~* History of diabetic ketoacidosis~* Cardiovascular/vascular diseases within 3 months of the enrollment~* Renal disease~* Hepatic diseases~* History of, or currently, acute or chronic pancreatitis~* Hematological and oncological disease/conditions~* Patients who have contraindications to therapy being studied~* Patients on weight loss program(s)~* Replacement or chronic systemic corticosteroid therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin 5 mg/ dapagliflozin 10mg or Placebo (Type: EXPERIMENTAL): Saxagliptin 5 mg /dapagliflozin 10 mg Placebo once a day orally
- Glimepiride or Placebo (Type: EXPERIMENTAL): Glimepiride or placebo 1mg or 2mg or 3mg or 4mg or 6mg once a day orally

Based on this trial design, predict the completion outcome and termination type (if applicable).